[1] |
Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994⁃2007: a comprehensive review of validation data and clinical results[J]. Br J Dermatol, 2008,159(5):997⁃1035. doi: 10.1111/j.1365⁃2133.2008.08832.x.
|
[2] |
VanBeek MJ. Integrating patient preferences with health utilities: a variation on health⁃related quality of life[J]. Arch Dermatol, 2008,144(8):1037⁃1041. doi: 10.1001/archderm.144. 8.1037.
|
[3] |
Seidler AM, Bayoumi AM, Goldstein MK, et al. Willingness to pay in dermatology: assessment of the burden of skin diseases[J]. J Invest Dermatol, 2012,132(7):1785⁃1790. doi: 10.1038/jid.2012.50.
|
[4] |
Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee[J]. J Am Acad Dermatol, 2018,78(1):148⁃155. doi: 10.1016/j.jaad.2017.08.037.
|
[5] |
中国医师协会皮肤科医师分会皮肤美容亚专业委员会. 中国玫瑰痤疮诊疗专家共识(2016)[J]. 中华皮肤科杂志, 2017,50(3):156⁃161. doi: 10.3760/cma.j.issn.0412⁃4030.2017.03.002.
|
[6] |
肖易, 陈丽萍, 敬丹榕, 等. 支付意愿在测量皮肤疾病负担中的意义与应用[J]. 中华皮肤科杂志, 2019,52(4):286⁃289. doi: 10.3760/cma.j.issn.0412⁃4030.2019.04.015.
|
[7] |
秦续龙, 郑亚明. 意愿支付法在药物经济学中的应用[J]. 中国药物经济学, 2009,(4):57⁃62. doi: 10.3969/j.issn.1673⁃5846. 2009.04.009.
|
[8] |
Xiao Y, Zhu W, Su J, et al. 259 Comparing willingness⁃to⁃pay and time⁃trade⁃off as the measures of burden of psoriasis: a pooled analysis of community, hospital, and web⁃based samples[J]. J Invest Dermatol, 2019,139(5, Suppl):S44.doi:10.1016/j.jid.2019.03.335.
|
[9] |
Baldwin HE, Harper J, Baradaran S, et al. Erythema of rosacea affects health⁃related quality of life: results of a survey conducted in collaboration with the National Rosacea Society[J]. Dermatol Ther (Heidelb), 2019,9(4):725⁃734. doi: 10.1007/ s13555⁃019⁃00322⁃5.
|
[10] |
Liluashvili S, Kituashvili T. Dermatology Life Quality Index and disease coping strategies in psoriasis patients[J]. Postepy Dermatol Alergol, 2019,36(4):419⁃424. doi: 10.5114/ada.2018. 75810.
|
[11] |
王冬雪, 刘浩, 杨彪, 等. 玫瑰痤疮患者的社会心理影响及其生活质量的研究现状[J]. 世界最新医学信息文摘(连续型电子期刊), 2018,18(92):58⁃60,62. doi: 10.19613/j.cnki.1671⁃3141.2018.92.026.
|
[12] |
Sampogna F. Life course impairment and quality of life over time[J]. Curr Probl Dermatol, 2013,44:47⁃51. doi: 10.1159/00035 0781.
|
[13] |
施琦, 赵志祥, 谢红付, 等. 玫瑰痤疮患者阵发性潮红的临床特征分析及对生活质量的影响[J]. 中华皮肤科杂志, 2020,53(5):340⁃344. doi: 10.35541/cjd.20191198.
|
[14] |
Menezes N, Moreira A, Mota G, et al. Quality of life and rosacea: pulsed dye laser impact[J]. J Cosmet Laser Ther, 2009,11(3):139⁃141. doi: 10.1080/14764170902741311.
|
[15] |
Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle⁃controlled double⁃blind trial[J]. Br J Dermatol, 2007,156(4):728⁃732. doi: 10.1111/j.1365⁃2133.2006.07669.x.
|
[16] |
Beikert FC, Langenbruch AK, Radtke MA, et al. Willingness to pay and quality of life in patients with atopic dermatitis[J]. Arch Dermatol Res, 2014,306(3):279⁃286. doi: 10.1007/s00403⁃013⁃1402⁃1.
|
[17] |
Beikert FC, Langenbruch AK, Radtke MA, et al. Willingness to pay and quality of life in patients with rosacea[J]. J Eur Acad Dermatol Venereol, 2013,27(6):734⁃738. doi: 10.1111/j.1468⁃3083.2012.04549.x.
|
[18] |
Tan J, Steinhoff M, Bewley A, et al. Rosacea: beyond the visible[EB/OL]. The BMJ hosted content, 2018[2020⁃08⁃09]. https://hosted.bmj.com/media/images/burden⁃of⁃rosacea⁃beyond⁃the⁃visible.pdf.
|